Titan Biotech Limited Submits SEBI Compliance Certificate for Q4 FY26

1 min read     Updated on 04 Apr 2026, 08:17 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Titan Biotech Limited filed its Q4 FY26 compliance certificate under SEBI Regulation 74(5) on April 4, 2026, covering the quarter ended March 31, 2026. The certificate, prepared based on confirmation from registrar Beetal Financial & Computer Services (P) Ltd, confirms proper handling of dematerialization processes including timely processing of securities, mutilation of certificates, and substitution of depositories as registered owners within mandated timeframes.

powered bylight_fuzz_icon
36859673

*this image is generated using AI for illustrative purposes only.

Titan Biotech Limited has submitted its quarterly compliance certificate to BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The submission demonstrates the company's adherence to mandatory reporting obligations for dematerialization processes.

Regulatory Compliance Filing

The compliance certificate was filed on April 4, 2026, addressing requirements under Regulation 74(5) of SEBI regulations for the quarter ended March 31, 2026. The document was signed by Charanjit Singh, serving as Compliance Officer with membership number A12726.

Filing Details: Information
Filing Date: April 4, 2026
Quarter Covered: Q4 FY26 (ended March 31, 2026)
Regulation: SEBI Regulation 74(5)
Compliance Officer: Charanjit Singh (M.No A12726)
Scrip Code: 524717

Registrar Confirmation Process

The compliance certificate was prepared based on confirmation received from Beetal Financial & Computer Services (P) Ltd, the company's SEBI-approved registrar and share transfer agent. Beetal Financial, holding SEBI registration number INR 000000262, provided its confirmation dated April 3, 2026.

The registrar's confirmation, signed by General Manager Punit Mittal, addressed several key compliance aspects:

  • Securities received from depository participants for dematerialization were properly confirmed to depositories
  • All securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed
  • Security certificates received for dematerialization were mutilated and cancelled after due verification
  • Depositories' names were substituted in the register of members as registered owners within the mandated 15-day period

Corporate Information

Titan Biotech Limited operates as an ISO 9001:2015 certified company with its registered office located at 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034. The company maintains its corporate identification number as L74999RJ1992PLC013387.

Company Details: Information
CIN: L74999RJ1992PLC013387
Office Address: 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034
Certification: ISO 9001:2015
Contact: 011-27355742, 71239900 (44 Lines)

Registrar and Transfer Agent Details

Beetal Financial & Computer Services (P) Ltd serves as the company's registrar and share transfer agent. The SEBI-approved category I registrar operates from Beetal House, 3rd Floor, 99 Madangir, Behind LSC, Near Dada Harsukhadas Mandir, New Delhi-110062.

This quarterly compliance filing represents part of the ongoing regulatory reporting requirements that publicly listed companies must fulfill to maintain transparency in their dematerialization processes and ensure proper handling of investor securities.

Historical Stock Returns for Titan Biotech

1 Day5 Days1 Month6 Months1 Year5 Years
+5.00%+21.20%+108.44%+69.27%+69.27%+69.27%

Will Titan Biotech's consistent regulatory compliance improve its ESG ratings and attract institutional investors in the coming quarters?

How might the company's ISO 9001:2015 certification and strong compliance record position it for potential partnerships or acquisitions in the biotech sector?

Could Titan Biotech's robust dematerialization processes indicate preparations for increased trading volumes or upcoming corporate actions?

1 Year Returns:+69.27%